| Code | CSB-RA006147MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US20140343258, targeting connective tissue growth factor (CTGF/CCN2). CTGF is a matricellular protein that plays a critical role in fibrosis, wound healing, and tissue remodeling by regulating extracellular matrix production, cell adhesion, and angiogenesis. This multifunctional growth factor is significantly upregulated in various fibrotic diseases including idiopathic pulmonary fibrosis, liver cirrhosis, systemic sclerosis, and diabetic nephropathy. Elevated CTGF expression is also implicated in cancer progression, where it promotes tumor growth, metastasis, and chemoresistance across multiple malignancies.
The reference antibody represents a therapeutic approach to neutralize CTGF activity and has been investigated for its potential in treating fibrotic disorders and oncological conditions. This biosimilar antibody provides researchers with a valuable tool for investigating CTGF-mediated signaling pathways, evaluating anti-fibrotic mechanisms, and exploring CTGF as a therapeutic target in disease models. It serves as an essential reagent for studying the pathophysiology of fibrosis and CTGF-driven pathological processes.
There are currently no reviews for this product.